<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75377">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01685944</url>
  </required_header>
  <id_info>
    <org_study_id>eki-619</org_study_id>
    <nct_id>NCT01685944</nct_id>
  </id_info>
  <brief_title>Anti-Obesity Effect of Pediococcus Pentosaceus LP28</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Pediococcus Pentosaceus LP28 on Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroshima University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hiroshima University</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate efficacy of Pediococcus pentosaceus LP28 in reducing body
      fat and body weight in subjects with BMI 25-30 kg/m2.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Body fat</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>BMI</measure>
    <time_frame>Every day (Overall 14 weeks)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Body weight will be measured every morning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal circumference</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum triglyceride</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood glucose</measure>
    <time_frame>Every 4 weeks (Overall 12 weeks)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting insulin</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-R</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistin</measure>
    <time_frame>Weeks 0 and 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Live Pediococcus pentosaceus LP28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heat-killed Pediococcus pentosaceus LP28</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Live Pediococcus pentosaceus LP28</intervention_name>
    <arm_group_label>Live Pediococcus pentosaceus LP28</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Heat-killed Pediococcus pentosaceus LP28</intervention_name>
    <arm_group_label>Heat-killed Pediococcus pentosaceus LP28</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI 25-30 kg/m2

        Exclusion Criteria:

          -  Taking medicines or functional food that may affect body weight or body fat

          -  Pregnant or nursing a child

          -  Participation in any clinical trial within 90 days of the commencement of the trial

          -  Renal or hepatic dysfunction

          -  Heart disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fumiko Higashikawa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hiroshima University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hiroshima University</investigator_affiliation>
    <investigator_full_name>Fumiko Higashikawa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
